Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Austar Lifesciences's share price for the quarter that ended in Dec. 2024 was HK$0.57. Austar Lifesciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 513 Mil. Therefore, Austar Lifesciences's market cap for the quarter that ended in Dec. 2024 was HK$292 Mil.
Austar Lifesciences's quarterly market cap
declined
from Dec. 2023 (HK$800 Mil) to Jun. 2024 (HK$354 Mil) and
declined
from Jun. 2024 (HK$354 Mil) to Dec. 2024 (HK$292 Mil).
Austar Lifesciences's annual market cap
declined
from Dec. 2022 (HK$1,035 Mil) to Dec. 2023 (HK$800 Mil) and
declined
from Dec. 2023 (HK$800 Mil) to Dec. 2024 (HK$292 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Austar Lifesciences's Enterprise Value for Today is HK$682 Mil.
Austar Lifesciences Market Cap Historical Data
The historical data trend for Austar Lifesciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Austar Lifesciences's Market Cap
For the Medical Devices subindustry, Austar Lifesciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austar Lifesciences's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Austar Lifesciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Austar Lifesciences's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Austar Lifesciences (HKSE:06118) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Austar Lifesciences Market Cap Related Terms
Thank you for viewing the detailed overview of Austar Lifesciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Austar Lifesciences Ltd is a China-based company engaged in providing engineering solutions to pharmaceutical manufacturers and research institutes. The business activity of the group is operated through Liquid and Bioprocess Systems; Clean Room and Automation Control and Monitoring Systems; Powder and Solid Systems; Good Manufacturing Practice (GMP) Compliance Services; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment segments. It derives the majority of revenue from the Liquid and Bioprocess System segment which is involved in providing solutions in pharmaceutical and water systems to treat water. The geographical business presence of the firm is seen across China and in other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06118 has been successfully added to your 